Context Therapeutics is expected to report a Q3 2026 net loss of $0.09 per share on zero revenue, while its current price of $0.20 sits far below the average analyst price target of $4.14. The central story for investors is the clinical execution of the CTIM-76 program, specifically the transition to an every-three-week dosing schedule for ovarian cancer patients.
Recent developments include the successful dosing of the first patient in the CT-202 Phase 1 trial in September 2026 and the discontinuation of the CT-95 asset to preserve capital. These strategic moves are designed to extend the company's cash runway into late 2027, ensuring focus on upcoming clinical readouts.